{"id":"https://openalex.org/W2331657708","doi":null,"title":"More indications approved and safety news for dabigatran etexilate.","display_name":"More indications approved and safety news for dabigatran etexilate.","alternate_titles":[],"publication_year":2014,"publication_date":"2014-12-01","ids":{"openalex":"https://openalex.org/W2331657708","mag":"2331657708","pmid":"https://pubmed.ncbi.nlm.nih.gov/25705315","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4316890"},"language":"en","primary_location":{"id":"pmh:oai:europepmc.org:3299269","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4316890","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},"parent_works":[],"lineage":["https://openalex.org/W2331657708"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4316890","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5106524946","display_name":"Mircea Cintez\u01ce","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I162051807","display_name":"Carol Davila University of Medicine and Pharmacy","ror":"https://ror.org/04fm87419","country_code":"RO","type":"education","lineage":["https://openalex.org/I162051807"]},{"id":"https://openalex.org/I4388891865","display_name":"Bucharest Emergency University Hospital","ror":"https://ror.org/051v1dy68","country_code":"RO","type":"healthcare","lineage":["https://openalex.org/I4388891865"]}],"countries":["RO"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Mircea Cinteza","raw_affiliation_strings":["\"Carol Davila\" University of Medicine and Pharmacy, Bucharest, Romania ; Emergency University Hospital of Bucharest, Romania","Carol Davila  University of Medicine and Pharmacy, Bucharest, Romania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\"Carol Davila\" University of Medicine and Pharmacy, Bucharest, Romania ; Emergency University Hospital of Bucharest, Romania","institution_ids":["https://openalex.org/I162051807","https://openalex.org/I4388891865"]},{"raw_affiliation_string":"Carol Davila  University of Medicine and Pharmacy, Bucharest, Romania","institution_ids":["https://openalex.org/I162051807"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5106524946"],"corresponding_institution_ids":["https://openalex.org/I162051807","https://openalex.org/I4388891865"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"9","issue":"4","first_page":"405","last_page":"407"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.9848999977111816,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.012600000016391277,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dabigatran-etexilate","display_name":"dabigatran etexilate","score":0.9800000190734863},{"id":"https://openalex.org/keywords/direct-thrombin-inhibitors","display_name":"direct thrombin inhibitors","score":0.8519999980926514},{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.9629999995231628},{"id":"https://openalex.org/keywords/non-valvular-atrial-fibrillation","display_name":"non-valvular atrial fibrillation","score":0.9629999995231628},{"id":"https://openalex.org/keywords/stroke-prevention","display_name":"stroke prevention","score":0.9210000038146973},{"id":"https://openalex.org/keywords/deep-vein-thrombosis","display_name":"deep vein thrombosis","score":0.9020000100135803},{"id":"https://openalex.org/keywords/pulmonary-embolism","display_name":"pulmonary embolism","score":0.9950000047683716},{"id":"https://openalex.org/keywords/re-ly-trial","display_name":"RE-LY trial","score":0.8759999871253967},{"id":"https://openalex.org/keywords/warfarin-comparison","display_name":"warfarin comparison","score":0.7850000262260437},{"id":"https://openalex.org/keywords/bleeding-risk","display_name":"bleeding risk","score":0.5680000185966492},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.44600000977516174},{"id":"https://openalex.org/keywords/long-term-anticoagulation","display_name":"long-term anticoagulation","score":0.6850000023841858}],"concepts":[{"id":"https://openalex.org/C2778810321","wikidata":"https://www.wikidata.org/wiki/Q419345","display_name":"Dabigatran","level":4,"score":0.8422877192497253},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5316850543022156},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25608259439468384},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.21534332633018494},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.11095759272575378}],"mesh":[],"locations_count":4,"locations":[{"id":"pmh:oai:europepmc.org:3299269","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4316890","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4316890","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4316890/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Maedica (Bucur)","raw_type":"Text"},{"id":"pmid:25705315","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25705315","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Maedica","raw_type":"Journal Article"},{"id":"mag:2331657708","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25705315","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3299269","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4316890","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1860620208","https://openalex.org/W1971941179","https://openalex.org/W2000438765","https://openalex.org/W2029758847","https://openalex.org/W2057308876","https://openalex.org/W2112378432","https://openalex.org/W2115348966","https://openalex.org/W2118092611","https://openalex.org/W2130909191","https://openalex.org/W2134430286","https://openalex.org/W2136489990","https://openalex.org/W2441750859"],"related_works":["https://openalex.org/W2587063264","https://openalex.org/W2259232498","https://openalex.org/W2376993443","https://openalex.org/W2159947853","https://openalex.org/W3083638498","https://openalex.org/W2149710276","https://openalex.org/W1983885439","https://openalex.org/W2040266997","https://openalex.org/W2037076482","https://openalex.org/W2401985010"],"abstract_inverted_index":{"For":[0],"more":[1,345,411,451,479],"than":[2,453,480],"50":[3],"years,":[4],"the":[5,20,28,38,93,125,130,167,179,184,219,266,273,312,315,320,323,358,484,489,497,500,535,552,569,579,584,603,632,641,644,649,659,661,674,687,692,717,735,746,786,795,827,838,849,865,873,917,920,942,955,974,984,991,998,1021,1035,1041],"only":[6],"oral":[7,44,71,502,1078],"anticoagulation":[8,203,975],"therapy":[9,32,259,507,719,736,985,999,1080],"available":[10],"was":[11,60,139,197,280,289,341,355,369,394,409,433,449,474,510,516,666,788,797,1038],"with":[12,233,260,287,305,382,428,508,625,758,763,848],"vitamin":[13],"K":[14],"antagonists.":[15],"The":[16,55,69,189,385,415,594,677,1032,1045],"difficulties":[17],"to":[18,106,281,371,534,551,568,583,690,716,734,745,833,896,903,915,970],"monitor,":[19],"instability":[21],"against":[22,325,331],"other":[23,94,326,850],"drugs":[24,329],"or":[25,330,706,883,989],"aliments":[26,332],"and":[27,36,82,120,150,152,158,169,178,244,263,292,300,319,343,377,391,425,441,464,476,483,544,559,566,573,588,610,614,638,673,681,702,720,724,728,740,751,771,775,781,802,826,840,846,899,927,947,995,1074],"risk":[29,387,430,490],"of":[30,43,129,143,154,201,210,228,256,276,314,317,322,360,389,401,431,446,491,521,537,554,571,586,602,654,663,671,679,694,722,748,779,792,809,814,817,842,844,864,875,893,919,930,941,960,976,986,990,1000,1023,1034,1085],"this":[31,112,340,600,934],"are":[33,96,104,141,269,890,958,1006],"well":[34],"known":[35,48],"studied.\r\n\r\nIn":[37],"last":[39],"years":[40,246,255,1013],"new":[41,207,501],"families":[42],"anticoagulants":[45,72],"were":[46,78,240,272,549,581,714,732,743,767,1010],"developed,":[47],"today":[49,485],"as":[50,290,293,295,404,434,436,643,647,667,669,789,791,1007,1009],"New":[51],"Oral":[52],"Anticoagulants":[53],"(NOAC).":[54],"first":[56,575],"one":[57],"clinically":[58],"studied":[59,105,140,631,898,905],"ximelagatran.":[61],"Its":[62],"hepatic":[63],"toxicity":[64],"stopped":[65],"it":[66,174,354,901,913],"for":[67,124,136,456,460,467,699,837,1081],"development.":[68],"next":[70,712],"who":[73],"accomplished":[74],"important":[75,336,1017,1070],"clinical":[76,110,118,191],"studies":[77,522,532,548,577,597,660,713,766],"dabigatran,":[79,261],"apixaban,":[80,853],"rivaroxaban":[81],"edoxaban.":[83],"From":[84],"these,":[85],"dabigatran":[86,132,138,288,363,418,472,509,538,619,664,695,835,867,946,968],"is":[87,496,512,914,950,1020,1049,1059,1068],"a":[88,366,398,519,525,870,891,1011,1027,1052,1082],"direct":[89,126],"thrombin":[90,127],"inhibitor,":[91],"while":[92,738,794],"three":[95],"factor":[97],"Xa":[98],"inhibitors.":[99],"However,":[100,888],"all":[101,658,953],"four":[102,531,576,765,819],"NOAC":[103,851,964],"date":[107],"in":[108,145,163,175,186,206,212,231,297,303,351,373,380,422,426,438,454,478,487,493,505,518,524,563,578,599,622,684,697,756,761,823,830,861,872,878,884,908,962,973,979,983,997,1051,1072],"similar":[109,399],"conditions.\r\n\r\nIn":[111],"paper":[113],"we":[114],"will":[115,858],"show":[116,1065],"some":[117,121,931],"results":[119,275,678,816],"adverse":[122],"effects":[123],"inhibitor":[128],"group,":[131],"etexilate.\r\n\r\nThe":[133],"main":[134,190,274,278],"indications":[135],"which":[137,193,506,857,963,1058],"prevention":[142,151,570,700,721,747,841,874],"stroke":[144,162,299,379,390,440,988],"non":[146,879],"valvular":[147,880,909,977,980],"atrial":[148,165,307,494,881,906,981],"fibrillation":[149,166,308,495,882,907],"treatment":[153,286,553,585,839],"deep":[155,555,885],"vein":[156,513,556,886],"thrombosis":[157,557],"pulmonary":[159,560],"embolism.\r\n\r\nFor":[160],"preventing":[161,298,488],"nonvalvular":[164],"Food":[168],"Drug":[170],"Administration":[171],"(FDA)":[172],"approved":[173],"October":[176],"2010":[177],"European":[180,688,828],"Medicine":[181,211],"Agency":[182],"did":[183,640],"same":[185,633,642],"August":[187],"2011.":[188],"study":[192,217,268,918],"granted":[194],"these":[195,470,818,1063],"approvals":[196],"RE-LY":[198,239,267],"(Randomized":[199],"Evaluation":[200],"Long-term":[202],"therapY),":[204],"published":[205,683],"England":[208],"Journal":[209],"2009":[213],"(1).":[214,346],"A":[215],"second":[216],"on":[218,247],"subject":[220],"followed":[221,241],"\u2013":[222],"RELY-ABLE":[223],"(Long":[224],"Term":[225],"Multi-center":[226],"Extension":[227],"Dabigatran":[229,1067],"Treatment":[230],"Patients":[232,237],"Atrial":[234],"Fibrillation)":[235],"(2).":[236],"from":[238,265],"between":[242,499,923,945,966],"2.3":[243],"4.7":[245],"dabigatran.":[248,928],"Data":[249,929],"showed":[250,397,784],"that":[251,283,357,670,785,1066],"even":[252,344,709,996],"over":[253,338],"6":[254],"long":[257,284,1076],"term":[258,285,1077],"advantages":[262],"safety":[264,675,772,796],"preserved.\r\n\r\nBut":[270],"what":[271],"RE-LY?\r\n\r\nIts":[277],"objective":[279],"demonstrate":[282],"effective":[291,435],"secure":[294,1075],"warfarin":[296,372,437,672],"systemic":[301,392,442],"embolism":[302,393,492,561,876],"patients":[304,350,381],"non-valvular":[306,383],"(AF).":[309],"If":[310],"so,":[311],"lack":[313],"necessity":[316],"monitoring":[318],"stability":[321],"molecule":[324],"concomitant":[327],"administered":[328],"would":[333],"offer":[334],"an":[335,939,1024,1069],"advantage":[337],"warfarin.\r\n\r\nAnd":[339],"demonstrated":[342],"On":[347],"18":[348],"113":[349],"44":[352],"countries":[353,482],"shown":[356],"dose":[359,653],"150":[361],"mg":[362,417],"etexilate":[364,419,473,665,696,836,868],"twice":[365],"day":[367],"(bid)":[368],"superior":[370],"reducing":[374,439],"both":[375],"ischemic":[376,987,993],"hemorrhagic":[378],"AF.":[384],"relative":[386],"reduction":[388],"35%.":[395],"It":[396],"rate":[400],"major":[402,540,591],"bleeding":[403,408,445,463],"warfarin,":[405,455,759,793],"but":[406,444,938],"intracranial":[407,468],"much":[410,450,798],"reduced":[412,452],"(by":[413],"59%).":[414],"110":[416],"bid,":[420],"given":[421],"old":[423],"people":[424],"those":[427],"higher":[429],"hemorrhage":[432],"embolism,":[443],"any":[447],"kind":[448],"instance":[457],"by":[458,465],"33%":[459],"life":[461],"threatening":[462],"70%":[466],"bleeding.\r\n\r\nFollowing":[469],"results,":[471],"registered":[475],"used":[477],"100":[481],"experience":[486],"largest":[498],"anticoagulants.\r\n\r\nAnother":[503],"field":[504],"developed":[511,517],"thrombosis.":[514,887],"This":[515,529],"series":[520],"grouped":[523],"program":[526,580,604],"called":[527],"RE-VOLUTION.":[528],"included":[530,598],"dedicated":[533,550,582,715,733,744],"use":[536,693],"after":[539,590,627,634,704,753],"orthopedic":[541,592],"surgery":[542],"(hip":[543],"knee":[545,635,707],"replacement),":[546],"two":[547,567],"(DVP)":[558],"(PE)":[562],"general":[564,718],"conditions":[565],"DVP":[572,587,750],"PE\r\n\r\nThe":[574],"PE":[589,703,752],"surgery.":[593],"phase":[595],"III":[596,1054],"part":[601],"were:":[605],"RE-NOVATE,":[606],"RE-NOVATE":[607,612,615,680],"II,":[608],"RE-MODEL":[609],"RE-MOBILIZE.":[611],"(3)":[613],"II":[616,730,783,804],"(4)":[617],"compared":[618],"once":[620],"daily":[621],"different":[623],"doses":[624],"enoxaparin":[626],"hip":[628,705],"replacement.":[629],"RE_MODEL":[630],"replacement":[636,708],"(5)":[637],"RE-MOBILIZE":[639],"former,":[645],"using":[646],"comparator":[648],"North":[650],"American":[651],"standard":[652],"enoxaparine":[655],"(6).":[656],"In":[657],"efficacy":[662,770,787],"good":[668,790],"similar.":[676],"RE-MODEL,":[682],"2007":[685],"lead":[686],"Commission":[689,829],"grant":[691],"EU":[698],"DVT":[701,723,845],"since":[710],"2008.\r\n\r\nThe":[711],"PE.":[725],"RE-COVER":[726,729,780,782,803],"(7)":[727],"(8)":[731],"itself,":[737],"RE-MEDY":[739,755],"RE-SONATE":[741,760],"(9)":[742],"recurrent":[749],"surgery:":[754],"comparison":[757,762],"placebo.\r\n\r\nAll":[764],"positive":[768],"regarding":[769],"(Tables":[773],"\u200b(Tables11":[774],"\u200band2).2).":[776],"Pooled":[777,806],"analysis":[778],"better":[799],"(10).\r\n\r\n\r\n\r\nTable":[800],"1\r\n\r\nRE-COVER":[801],"-":[805,812,856],"Analysis":[807],"summary":[808,813,1033],"results.\r\n\r\n\r\n\r\n\r\n\r\nTable":[810],"2\r\n\r\nRE-MEDY":[811],"results.\r\n\r\n\r\n\r\nThe":[815],"trials":[820],"determined":[821],"FDA":[822],"April":[824],"2014":[825,832],"June":[831],"approve":[834],"recurrence":[843],"PE\r\n\r\nTogether":[847],"(rivaroxaban,":[852],"maybe":[854],"edoxaban":[855],"be":[859,897,904,971],"commented":[860],"future":[862],"issues":[863],"Journal)":[866],"constitutes":[869],"milestone":[871],"either":[877],"there":[889,957],"lot":[892],"things":[894],"still":[895],"resolved.\r\n\r\nFirst,":[900],"has":[902],"heart":[910],"disease.":[911],"Second,":[912],"finalize":[916],"suspected":[921],"association":[922,935],"acute":[924,1001],"coronary":[925,1002],"syndromes":[926],"authors":[932],"found":[933],"nonsignificant":[936],"(11),":[937],"explanation":[940],"possible":[943],"linkage":[944],"myocardial":[948],"infarction":[949],"not":[951],"at":[952,1040],"identified.\r\n\r\nOn":[954],"contrary,":[956],"fields":[959],"research":[961],"and,":[965],"them,":[967],"have":[969],"studied:":[972],"prosthesis,":[978],"fibrillation,":[982],"transient":[992],"attacks":[994],"syndromes.":[1003],"These":[1004],"objectives":[1005],"actual":[1008],"few":[1012],"before":[1014],"(12).":[1015],"One":[1016],"step":[1018],"forward":[1019],"development":[1022],"antidote,":[1025],"aDABI-Fab,":[1026],"Fab":[1028],"monoclonal":[1029],"antibody":[1030],"(13).":[1031],"Phase":[1036,1053],"I/II":[1037],"presented":[1039],"AHA":[1042],"2013":[1043],"Congress.":[1044],"product,":[1046],"named":[1047],"idarucizumab,":[1048],"now":[1050],"study,":[1055],"RE-VERSE":[1056],"AD,":[1057],"actively":[1060],"enrolling":[1061],"patients.\r\n\r\nAll":[1062],"data":[1064],"achievement":[1071],"efficient":[1073],"anticoagulant":[1079],"large":[1083],"category":[1084],"patients.":[1086]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2331657708","counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
